Molecular and Cellular Biology, August 2001, p. 4919-4928, Vol. 21, No. 15
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.15.4919-4928.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
andDepartment of Microbiology and Immunology, The University of Michigan Medical School, Ann Arbor, Michigan 48109
Received 19 December 2000/Returned for modification 20 February 2001/Accepted 1 May 2001
| |
ABSTRACT |
|---|
|
|
|---|
The major histocompatibility complex (MHC) class II transactivator (CIITA) regulates the expression of genes involved in the immune response, including MHC class II genes and the interleukin-4 gene. Interactions between CIITA and sequence-specific, DNA-binding proteins are required for CIITA to function as an activator of MHC class II genes. CIITA also interacts with the coactivators CBP (also called p300), and this interaction leads to synergistic activation of MHC class II promoters. Here, we report that CIITA forms complexes with itself and that a central region, including the GTP-binding domain is sufficient for self-association. Additionally, this central region interacts with the C-terminal leucine-rich repeat as well as the N-terminal acidic domain. LXXLL motifs residing in the GTP-binding domain are essential for self-association. Finally, distinct differences exist among various CIITA mutant proteins with regard to activation function, subcellular localization, and association with wild-type protein and dominant-negative potential.
| |
INTRODUCTION |
|---|
|
|
|---|
Major histocompatibility complex (MHC) class II molecules present exogenously derived antigenic peptides to CD4+ T cells. The recognition of alien peptide by these T cells allows a host to immunologically respond to foreign pathogens. MHC class II molecules are constitutively expressed on B cells and dendritic cells and inducible upon other cells, such as macrophages, all of which are capable of the uptake and processing of foreign invaders. In the absence of MHC class II molecules, individuals are unable to mount a T-cell-mediated immune response and overwhelming infection ensues. A group of immunodeficient patients which lack MHC class II molecules have been identified, and this disease has been coined bare lymphocyte syndrome (BLS) (8, 15). One class of these BLS patients (group A) lack MHC class II molecules on their cellular surfaces due to a defect in the MHC class II transactivator, CIITA (38).
The regulation of MHC class II gene expression is primarily at the transcriptional level. The promoters of MHC class II genes contain at least four conserved sequences: the S, X, X2, and Y boxes (reviewed in reference 28). These cis-acting elements are occupied by sequence-specific transcription factors; the heterotrimeric NF-Y complex binds to the Y box (25), the multimeric RFX proteins bind to the S and X boxes (10, 21), and the cyclic AMP response element binding protein (CREB) binds to the X2 box (31). Protein-protein interactions stabilize the binding of these proteins to MHC class II promoter DNA as illustrated by interactions between the RFX complex and NF-Y (33, 40, 41). and the enhancement of RFX complex binding facilitated by CREB (27, 41). However, the binding of all of these transcription factors to their respective cis-acting elements is insufficient to lead to MHC class II promoter activity. CIITA is required for both the constitutive and the gamma interferon-inducible expression of MHC class II genes (4, 38, 39). CIITA does not bind directly to DNA. The exact mechanism of CIITA action is not known, but it is thought that the interaction of CIITA with sequence-specific DNA binding proteins, as well as the basal transcriptional machinery, is required for its function (see below). Therefore, it is not surprising that CIITA can act as an activator and a repressor depending on the target promoter (14, 36).
CIITA contains four domains
acidic (A), proline-serine-threonine-rich
(PST), GTP-binding domain (GBD), and leucine-rich repeat (LRR)
all of
which are required to activate the MHC class II promoter. The acidic
transcriptional activation domain interacts with TAFII32 (12). Recruitment of the coactivator protein CBP (also
known as p300) by the acidic domain has also been reported and shown to
lead to synergistic activation of MHC class II promoters and the
repression of the interleukin-4 (IL-4) promoter (13, 23, 36). The PST domain is essential for CIITA function but the role
of this domain remains unknown (6). The binding of GTP to the GBD is required for efficient translocation of CIITA from the cytoplasm to the nucleus (17). The GBD of CIITA
contains three consensus motifs for GTP binding: a P-loop-Walker A
motif (421GKAGQGKS428), a magnesium
coordination site (462DAYG465), and a motif
likely to confer GTP-binding specificity
(559SKAD562). Mutation in any of these sites
significantly reduces transactivation activity (6). The
GBD also contains two LXXLL motifs (466LQDLL470
and 526LRGLL530). These motifs serve as
protein-protein interaction domains exemplified by their role in the
interaction between ligand-bound nuclear hormone receptors and their
coactivators (18, 32). To date, no specific interaction
between these LXXLL motifs and other proteins have been identified;
however, they are essential for CIITA function (3). Recent
work has established that there are multiple interactions CIITA forms
with the DNA-binding proteins that bind the MHC class II promoter,
including RFX5 and RFXANK, NF-YB and NF-YC, and CREB (9, 16,
43). Except for RFXANK and NF-YC, which bind the amino-terminal
region of CIITA, the GBD of CIITA serves as the likely domain for these
interactions. Along with these properties, the GBD interacts with the
amino terminus of the coactivator p300 (36). The fourth
domain of CIITA contains at least four LRRs. The CIITA LRR falls into
the ribonuclease inhibitor-like subfamily of LRR-containing proteins
characterized by a XXXLXXLXLXXN/CXLXXXGOXXLXXOLXX (L,
leucine; X, any amino acid; O, nonpolar residue; "G", indicates more than 30% identity) repeat (22). One role of LRR
domains is to mediate protein-protein interactions (30,
34). CIITA proteins with LRR truncations and LRR mutations
cannot activate the MHC class II promoter, suggesting that all four
repeats are required for transactivation potential (5,
16).
NOD1, an Apaf-1-like molecule which plays an important role in cell death, shares a similar domain organization with CIITA: an effector domain, a nucleotide-binding domain, and an LRR domain (19). Importantly, NOD1 self-association is critical for its function (19, 20). Based on these observations, we sought to determine if CIITA could form complexes with itself and if self-association was required for CIITA to activate MHC class II promoters. We document that CIITA interacts with itself through LXXLL motifs found in a 162-amino-acid region which includes the GTP-binding domain. In addition to associating with itself, this domain also interacts with the amino and carboxyl portions of the protein. Multiple mutants of CIITA were analyzed and differed in their ability to activate MHC class II promoters, interact with wild-type CIITA, and act as dominant-negative proteins.
| |
MATERIALS & METHODS |
|---|
Cell culture and transfections.
The human kidney cell line
293T was maintained in Clicks medium with 10% fetal bovine serum, 100 U of penicillin per ml, 100 µg of streptomycin per ml, 2 mM
L-glutamine, and 10
5 M
-mercaptoethanol.
Cells were grown at 37°C with 5% CO2. Transfection of
293T cells for functional assays and biochemical interactions was
performed using the calcium phosphate method. For reporter gene assays,
105 cells were plated in 12-well plates and transfected
with 0.1 µg of reporter construct, 0.1 µg of CIITA plasmid, and 0.1 µg of
-galactosidase expression vector per well. Samples were run in duplicate for each experiment. For biochemical assays,
106 cells were plated in 10-cm plates and transfected with
8 µg of each CIITA plasmid, unless otherwise indicated in the text.
Raji and RJ2.2.5 cells were maintained in RPMI containing the same supplements as for the 293T cells. To generate stable transfectants of
RJ2.2.5 cells, 5 × 106 RJ2.2.5 cells were mixed with
25 µg of DNA in 500 µl of medium, followed by electroporation (250 V, 960 µF). Cells were then selected under 1 mg of G418 per ml.
Plasmid constructs.
The E
-luciferase containing 2 kb of
E
promoter (BglI-BalI) and the cytomegalovirus
promoter-driven
-galactosidase (14), hemagglutinin
(HA)-tagged wild-type CIITA (11), FLAG-tagged wild-type
CIITA, and FLAG-CIITA(1-1130, K427E) (5, 6) have been
previously described. All constructs were made using the expression
vector pCDNA3 containing an HA or FLAG epitope at the N terminus.
PCR-mediated mutagenesis was used to generate internal deletion and
amino acid substitution mutants. The primers used to generate mutants
are shown below, followed by their usage. The number indicates the
starting position of the primer that corresponds to the published human
CIITA cDNA sequence (38), and the "5-" or "3-"
indicates the direction of priming: 5-116 with EcoRI and the
FLAG tag,
CTGGAATTCATGGACTACAAAGACGATGACGATAAACGTTGCCTGGCTCCA; 5-308 with EcoRI and FLAG tag,
CTGGAATTCATGGACTACAAAGACGATGACGATAAATACTCAGAACCCGACACA; 5-377 with EcoRI and FLAG tag,
CTGGAATTCA TGGACTACAAAGACGATGACGATAAAGATGAAGAGACCAGGGAG; 5-584 with ClaI, CCATCGATCACTGGAAGCCAGCTGAG;
5-584 with EcoRI and FLAG tag,
CTGGAATTCATGGACTACAAAGACGATGACGATAAAATGCACTGGAAGCCAGCTGAG; 5-1334 with XbaI,
TGCTCTAGACACCGGCGGCCGCGTGAGACACGAGTG; 5-1335 with LXXLL
substitution, CACCGGCGGCCGCGTGAGACACGAGTGATTGCTGTGCTG; 5-1499 with LL-to-AA substitution,
GCCTATGGCCTGCAGGATGCGGCCTTCTCCCTGGGCCCACAG; 5-1502 with
LXXLL substitution,
CGTCCGGGGGATGCCTATGGCGCGGCGGCTGCGGCCTTCTTCCTGGGCCCACAGCCA; 5-1682 with LXXLL substitution,
TGCTCCGCCGCGGCTGCGGCGGCCGGCCTTTTCCAGAAGAAG; 3-307 with
ClaI, CCATCGATGAGCTCAATCTCTTCTTCTCC; 3-376 with
ClaI, CCATCGATACCTTCCATGTCACACAACAG; 3-466 with
ClaI, CCATCGATGTCCTTGCTCAGGCCCTC; 3-1099, ATGCTCGAGTCAGGAGACCTCTCCAGCTGCCGG; 3-1101,
TTGGAGACCTCTCCAGCTGCC; 3-1528 with LXXLL substitution,
GGAGAAGGCCGCAGCCGCCGCGCCATAGGCATCCCCCGGACG; 3-1528 with
LL-to-AA substitution,
GGAGAAGGCCGCATCCTGCAGGCCATAGGCATCCCCCGGACG; 3-1708 with LXXLL substitution,
GCCGGCCGCCGCAGCCGCGGCGGAGCAGGGCTCCGCCGGTGC; 3-1890, TCTTGGTGCTCTGTCATCCCT; 5-584 with an EcoRI
site and the FLAG tag,
CTGGAATTCATGGACTACAAAGACGATGACG ATAAAATGCACTGGAAGCCAGCTGAG; and 3-1099 with XhoI, ATGCTCGAGTCAGGAGACCTCTCCAGCTGCCGG.
Flow cytometry. Cells were washed and resuspended in cold 1× phosphate-buffered saline (PBS) supplemented with 1% fetal bovine serum. Staining was performed in the same buffer, and samples were analyzed on a FACScan (Becton Dickinson). W6/32 and L243 were used for MHC class I and class II analyses, respectively.
Luciferase assays.
At 2 days posttransfection, cells were
harvested, washed with 1× PBS, and lysed in 1× Reporter lysis buffer
(Promega, Madison, Wis.). One-half of the lysate was used for the
luciferase assay, and one-third of the lysate was used for the
-galactosidase assay as previously described (14).
-Galactosidase readings were used to normalize the relative
luciferase activity of each sample for all transfections.
Immunoprecipitation and Western blotting.
At 2 days
posttransfection, the cells were harvested and washed with 1× PBS.
Whole-cell lysates were made by resuspending the cell pellet in 100 µl of ice-cold lysis buffer (1% Triton X-100, 25 mM Tris [pH 7.4],
150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 10 µg of
leupeptin per ml, 10 µg of aprotonin per ml) for 1 h on ice.
Cytoplasmic and nuclear fractions were prepared as described previously
(7). For whole-cell and subcellular fractionation, 8 µg
of each lysate was saved for analysis of protein expression (designated
lysate or "L" in text), and the remainder was normalized to equal
levels and resuspended in 500 µl of ice-cold lysis buffer and
precleared with protein A-Sepharose (Pharmacia, Piscataway, N.J.). Then
2 µg of anti-HA antibody (Santa Cruz Biotech, Santa Cruz, Calif.) was
added to the precleared lysates and incubated for 1 h on ice. A
total of 25 µl of protein A-Sepharose (50% slurry) was added per
immunoprecipitation reaction and rotated at 4°C for 3 to 8 h.
Reactions were next spun at 660 × g for 5 min to pellet the Sepharose beads and then washed with cell lysis buffer. This
process was repeated twice more, and then the pellet was resuspended in
sodium dodecyl sulfate (SDS) loading buffer. Proteins were resolved on
SDS-polyacrylamide gel electrophoresis (PAGE) gels and transferred to
polyvinylidene difluoride (Millipore, Bedford, Mass; NEN, Boston,
Mass.) using a semidry gel electrophoresis apparatus (Bio-Rad,
Hercules, Calif.). Membranes were blocked in 1× Tris-buffered saline
(pH 7.4) containing 0.05% Tween 20 (TBS-T), 1% bovine serum albumin,
and 4% dry milk overnight at 4°C and probed with anti-FLAG (M2;
Sigma, St. Louis, Mo.), anti-HA (Santa Cruz Biotech), anti-GRP78 (N-20;
Santa Cruz Biotech), or anti-p300 (N-15; Santa Cruz Biotech) antibodies
in blocking solution for at least 1 h at room temperature.
Membranes were washed three times in TBS-T for 15 min each and then
probed with horseradish peroxidase-conjugated secondary antibodies
(Jackson Immunoresearch Laboratories, West Grove, Pa.) in blocking
solution for 1 h at room temperature. Membranes were washed five
times in TBS-T for 15 min each time and then analyzed by using
chemiluminescence (NEN). Blots were stripped in stripping solution
(62.5 mM Tris, pH 6.7; 2% SDS; 100 mM
-mercaptoethanol) and placed
at 50°C for 30 min, washed in TBS-T for 1 h, and then blocked
and probed as previously described.
In vitro transcription and translation and in vitro binding assays. We performed 100-µl in vitro transcription and translation reactions according to the manufacturer's suggested protocol (Promega). For the in vitro binding assays, the products of the in vitro transcription and translation reactions, or equal amounts of cell lysates, in microgram quantities as determined by protein assay (Bio-Rad), made from different plates of 293T cells were mixed together on ice in a total volume of 600 µl of cell lysis buffer containing 150 mM NaCl for 2.5 h, with inversion of the tubes every 30 min. Immunoprecipitation reactions were performed as described above. One-twentieth of each lysate or in vitro reaction was saved for analysis of input protein.
| |
RESULTS |
|---|
|
|
|---|
Cellular, but not in vitro transcribed and translated, CIITA forms
complexes with itself.
The purpose of our study was to determine
whether CIITA associates with itself, which may affect its ability to
transactivate the MHC class II gene. Therefore, it is important to
assess the amount of CIITA protein which can be detected using our
detection systems. To do this, a constant amount of MHC class II
promoter-driven luciferase was transfected into 106 293T
cells with an increasing amount of FLAG-tagged wild-type CIITA
expression plasmid (Fig. 1A). The levels
of CIITA protein and induction of MHC class II
promoter activity were measured by Western blot and luciferase
activity, respectively. We were unable to detect CIITA protein if less
that 1.25 µg of CIITA plasmid was transfected (Fig. 1B, top panel).
Loading twice the amount of cell lysate (16 versus 8 µg) and a longer
exposure did not produce detectable levels of CIITA below this point
(data not shown). However, these undetectable levels of CIITA protein
were sufficient to activate the MHC class II promoter, indicating that CIITA is a potent transcription factor (Fig. 1B). Based on these data,
and in order to visualize CIITA interactions, 8 µg of CIITA expression vector was used for transfection throughout our study, unless otherwise noted. This level most probably lead to an
overexpression of CIITA protein. However, the inability to perform
experiments with multitagged CIITA protein from endogenous levels of
CIITA, in addition to the vast number of interactions that CIITA has with other proteins while residing in cells (see Discussion), led us to
use a transfection system to visualize CIITA self-interactions.
|
Analysis of acidic domain mutants.
The data that wild-type
CIITA did not interact with the mutant lacking the acidic domain led us
to further investigate the importance of this domain. CIITA expression
constructs which contain deletions of different regions of the acidic
domain were made and tested for their ability to transactivate the MHC
class II promoter (Fig. 2A). All mutants
were incapable of activation except mutant CIITA(1-64:158-1130),
which could transactivate but only at 25% of the level of wild-type
protein (Fig. 2B). A CIITA mutant lacking the entire acidic domain has
been previously shown to be a potent dominant-negative protein
(42). We therefore tested the dominant-negative activity
of each mutant by cotransfecting the mutants with the MHC class II
promoter-driven reporter in the presence of wild-type CIITA. Various
levels of dominant-negative function were observed (Fig. 2C, lanes 2 to
6). CIITA(1-64:158-1130), the only mutant to have some activation
function, had the least ability to repress wild-type protein, while
CIITA(88-1130) could block most of the wild-type CIITA function.
Finally, these mutants were tested for their ability to interact with
wild-type protein. None of the mutants showed detectable levels of
association (Fig. 2D). This indicates that the entire acidic domain is
required for self-association which, in turn, seems to be necessary to activate the MHC class II promoter. CIITA(1-64:158-1130) may undergo self-association, but the degree of association may be too low to be
detected.
|
A 162-amino-acid region containing the GTP-binding domain is
sufficient for self-association.
Since the mutant lacking the
acidic domain did not self-associate, we next tested whether the acidic
domain by itself could self-associate. When amino acids 1 to 331 containing the A/PST region (HA-1-331) was coexpressed with the
FLAG-tagged version of itself, it did not self associate (Fig.
3B, lane 1). However, it did associate
with CIITA(408-857) containing the GBD (Fig. 3B, lane 2). The PST
domain by itself, CIITA(157-329), did not associate with
CIITA(408-857) (Fig. 3B, lane 4). This suggests that the acidic
domain, in the context of CIITA(1-331), is the region which is binding
to CIITA(408-857). Finally, the LRR, CIITA(980-1130), did not
interact with CIITA(1-331) or associate with itself (Fig. 3B, lanes 3 and 5). Together, neither the N-terminal nor the C-terminal domains of
CIITA associate with each other or with themselves.
|
LXXLL motifs, but not GTP binding, are necessary for
self-association.
Since CIITA(408-857) could form complexes with
itself, we sought to further characterize this domain.
CIITA(408-857) harbors GTP-binding motifs which, when mutated in
the context of full-length CIITA, inhibits GTP binding and nuclear
translocation (17). Therefore, we asked if GTP binding
plays a role in mediating self-association. To test this, we created a
construct that expresses CIITA(408-857) with a substitution in the
P-loop region necessary for GTP binding: CIITA(408-857)K427E (Fig.
4A, thin line). When
FLAG-CIITA(408-857) or FLAG-CIITA(408-857)K427E were
tested for association with HA-CIITA(408-570), both showed interaction
(Fig. 4B). This implies that GTP binding is not a prerequisite for
self-association of this region.
|
LXXLL motifs in the context of full-length CIITA are critical for transactivation potential, subcellular localization, and self-association. Our data suggest that the intact LXXLL motifs are important for self-association. However, this was demonstrated by using a smaller domain and not the entire protein. To determine whether the same motifs are also important for self-association in the context of the full-length protein, we generated a full-length CIITA containing substitutions at both LXXLL motifs, LXXLL(466, 526). We also replaced five amino acids of each LXXLL motif individually with alanine, generating LXXLL(466) and LXXLL(526). In addition, two leucine residues, amino acids 469 and 470, were substituted with alanine (LL-AA). We first tested if the LXXLL mutants could activate the MHC class II promoter. None of the LXXLL substitutions were able to transactivate the MHC class II promoter except LXXLL(526) which showed partial activity (Figure 5A).
We next asked whether the LXXLL mutants behave the same with regard to endogenous MHC class II genes. To do this, each LXXLL mutant was stably transfected into RJ2.2.5 B cells which do not express MHC class II due to a defect in the CIITA gene (1, 38). Stable transfectants were selected and tested for MHC expression by flow cytometric analysis. Consistent with the transient-transfection data, LXXLL(526) could not completely restore endogenous MHC class II expression in RJ2.2.5 cells (Fig. 5B). LXXLL(466) and LXXLL(466, 526) did not lead to MHC class II expression in these cells (data not shown). Together, these data suggest that the first LXXLL motif is critical for CIITA function.
|
| |
DISCUSSION |
|---|
|
|
|---|
CIITA is known to exert its transactivation function by interacting with other proteins that bind the MHC class II promoter (11-13, 23, 29, 35, 40, 43). Here, we observe that self-association of CIITA appears to be important for CIITA function, which may serve as an additional regulatory event for MHC class II gene transcription. Many DNA-binding proteins and coactivators interact with overlapping regions of CIITA, predominantly through the acidic domain and the GBD (9, 16, 43). How can CIITA form contacts with all of these proteins simultaneously? One solution may be that only a subset of DNA-binding proteins directly contact CIITA, while the rest are associated with CIITA through another protein(s) which is already bound to CIITA. Another possibility is that the formation of a CIITA complex might work to expose binding surfaces on CIITA, making its conformation competent to bind multiple DNA-binding proteins simultaneously. The role that the MHC class II promoter plays in orchestrating these events deserves further analysis.
We identified the central region of CIITA, amino acids 408 to 570 containing the GTP-binding and LXXLL motifs, as playing an important role in CIITA self-association. This region interacts with itself, the amino-terminal domain of CIITA (A/PST), and the carboxyl-terminal LRR (Fig. 3). Therefore, the central region containing the GBD is a focal point for interactions with multiple domains, which is in agreement with recently published work (26). We demonstrated that the acidic domain plays a critical role for self-association since mutants lacking the acidic domain cannot self-associate. However, the A/PST domain by itself could not self-associate. This indicates that the interaction of the acidic domain with CIITA(408-857) may be essential for the proper folding of CIITA proteins necessary for CIITA complex formation. On the other hand, the LRR is dispensable for self-association but required for CIITA transactivation potential (Fig. 1C and reference 16, respectively).
Interestingly, the coactivators CBP interact with CIITA through the acidic domain (13, 23), as well as through CIITA(408-857) (36). Hence, these interactions may facilitate CIITA self-association by providing this proper folding, which brings the acidic domain and the GBD together. It is tempting to speculate that acetylation of CIITA by CBP may be required for this process, but this remains to be proven.
Although the CIITA(408-570) region was sufficient for self-association, whether or not CIITA complex formation results from this region interacting with itself or with other regions in the context of full-length protein remains to be determined. Since we could not detect the self-association of the acidic domain with itself or the LRR with itself, there are several possible interactions which may account for the observed self-association of full-length CIITA. These include interactions between either the acidic domain, the LRR, or the GBD region from one CIITA molecule interacting with the GBD region of another CIITA molecule. It has recently been shown that amino acids 700 to 1130, including the LRR, are capable of self-association (26). In contrast, we could not detect self-association of the LRR domain encompassing amino acids 980 to 1130 (Fig. 3B). This implies, therefore, that residues residing between amino acids 700 and 980 might be capable of self-association. Indeed, we have recently observed self-association of a fragment of CIITA within this region, CIITA(864-979) (T. J. Sisk and C.-H. Chang, unpublished data). Hence, the self-association of 1-335:700-1130 observed by Linhoff et al. may be mediated by this LRR proximal region not by the LRR. Further studies are required to determine the stoichiometry and the orientation of CIITA interaction in relation to DNA-binding proteins.
The analysis of CIITA proteins with mutated acidic domains reveals a relationship between the ability of CIITA self-association and transactivation potential. In particular, CIITA(88-1130) was highly similar to wild-type CIITA in expression level and nuclear and cytoplasmic localization (Fig. 5C). CIITA(88-1130) also retained the ability to interact with CBP, albeit at a lower level than that of the wild type (Sisk and Chang, unpublished). However, the same mutant failed to transactivate the MHC class II promoter and to self-associate (Fig. 2). Therefore, the lack of self-association may be at least partly responsible for the loss of transactivation function of CIITA(88-1130). CIITA mutants which possess these traits may preclude the formation of a functional enhanceosome complex required for gene activation (29) which forms on an intact MHC class II promoter.
LXXLL motifs are shown to play a critical role for transcriptional regulation by facilitating protein-protein interactions (18, 32). Therefore, the same motif in CIITA may mediate a similar interaction of CIITA with itself. Alternatively, the LXXLL motifs may be recognized by an unidentified element(s) necessary for complex formation since in vitro-transcribed and -translated CIITA protein failed to associate with itself. The same element may be required for CIITA nuclear localization in that it might be possible that CIITA interacts with a nuclear membrane protein(s) through LXXLL motifs, which then leads to translocation. Since the LXXLL motif is involved in both self-association and nuclear trafficking, the two events seem related. However, it is not yet clear where in the cellular compartments CIITA association occurs since our data only allow a glimpse of the steady-state level of self-associated CIITA and do not necessarily indicate the site of association. The relationship between the dynamics of CIITA self-association and the nuclear trafficking requires further study.
Since CIITA shares strikingly similar domain organization with NOD1 and Apaf-1, it is noteworthy to mention that self-association of NOD1 and Apaf-1 is required for their function (2a, 19). Apaf-1 and NOD1 are proteins which regulate the activation of enzymes involved in cell death by forming self-complexes, which leads to the activation of downstream molecules in the cell death pathway (2, 19). For Apaf-1, the recognition of a binding partner which binds the carboxyl-terminal regulatory domain is thought to induce the self-association of these proteins (24, 44). Thus, CIITA may undergo a similar conformational change to interact with itself and subsequently with other proteins on the MHC class II promoter. It is not yet clear what might regulate the initial unfolding of CIITA.
CIITA is a potent transcription factor since undetectable levels of CIITA by Western blot were sufficient to activate the MHC class II gene (Fig. 1B). Therefore, it is possible that a cell does not require a high level of self-associated CIITA. Indeed, a recent study reported that approximately 1% of total CIITA was associated with the MHC class II promoter in B cells, but this study did not address whether CIITA presents as a self-associated complex (29). Hence, it would be difficult to observe endogenous CIITA as a complex in B cells. In fact, less than 1% of CIITA in B cells was detectable as a high-molecular-weight complex revealed by gels run under semidenatured conditions (Sisk and Chang, unpublished). However, because CIITA interacts with multiple proteins, it is not possible to conclude whether CIITA seen as a high-molecular-weight complex was composed solely of CIITA or other proteins. We therefore were forced to use the overexpression transfection system to study these interactions. The interactions observed appeared to be specific since there were multiple mutants which failed to associate with the wild-type protein even when overexpressed. Further studies are warranted to determine the degree of self-association of endogenous levels of CIITA.
| |
ACKNOWLEDGMENTS |
|---|
We thank Naohiro Inohara and Gabriel Nunez for stimulating discussions of published and unpublished data and Jenny Ting for CIITA expression plasmids. We also express our immense appreciation to Wes Dunnick and Ormond MacDougald and to Tania Gourley for critical review of the manuscript.
This work was supported in part by National Institutes of Health grant AI41510 to C.-H. Chang and Immunology Training Grant T32-AI07413 to T. J. Sisk.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Microbiology and Immunology, The University of Michigan Medical School, 6606 Medical Sciences Building II, Ann Arbor, MI 48109-0620. Phone: (734) 647-7666. Fax: (734) 764-3562. E-mail: heechang{at}umich.edu.
Present address: Department of Cardiovascular Science, Pfizer, Ann
Arbor, MI 48105.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Accolla, R.
1983.
Human B cell variants immunoselected against a single Ia antigen subset have lost expression of several Ia antigen subsets.
J. Exp. Med.
157:1053-1058 |
| 2. |
Benedict, M. A.,
Y. Hu,
N. Inohara, and G. Nunez.
2000.
Expression and functional analysis of Apaf-1 isoforms. Extra Wd-40 repeat is required for cytochrome c binding and regulated activation of procaspase-9.
J. Biol. Chem.
275:8461-8468 |
| 2a. |
Bertin, J.,
W.-J. Nir,
C. M. Fischer,
O. V. Tayber,
P. R. Errada,
J. R. Grant,
J. J. Keilty,
M. L. Grosselin,
K. E. Robison,
G. H. W. Wong,
M. A. Glucksmann, and P. S. DiStefano.
1999.
Human CARDY protein is a novel CED-4/Adaf-1 cell death family member that activates NF- B.
J. Biol. Chem.
274:12955-12958 |
| 3. |
Brown, J. A.,
E. M. Rogers, and J. M. Boss.
1998.
The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element.
Nucleic Acids Res.
26:4128-4136 |
| 4. |
Chang, C.-H.,
J. Fontes,
M. Peterlin, and R. A. Flavell.
1994.
Class II, transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes.
J. Exp. Med.
180:1367-1374 |
| 5. | Chin, K. C., G. Li, and J. P. Ting. 1997. Activation and transdominant suppression of MHC class II and HLA-DMB promoters by a series of C-terminal class II transactivator deletion mutants. J. Immunol. 159:2789-2794[Abstract]. |
| 6. |
Chin, K.-C.,
G. G.-X. Li, and J. P.-Y. Ting.
1997.
Importance of acidic, proline/serine/threonine-rich, and GTP-binding regions in the major histocompatibility complex class II transactivator: generation of transdominant-negative mutants.
Proc. Natl. Acad. Sci. USA
94:2501-2506 |
| 7. | Cressman, D. E., K. C. Chin, D. J. Taxman, and J. P. Ting. 1999. A defect in the nuclear translocation of CIITA causes a form of type II bare lymphocyte syndrome. Immunity 10:163-171[CrossRef][Medline]. |
| 8. | dePreval, C., B. Lisowska-Grospierre, M. Loche, C. Griscelli, and B. Mach. 1985. A trans-acting class II regulatory gene unlinked to the MHC controls expression of HLA class II genes. Nature 318:291-293[CrossRef][Medline]. |
| 9. |
DeSandro, A. M.,
U. M. Nagarajan, and J. M. Boss.
2000.
Associations and interactions between bare lymphocyte syndrome factors.
Mol. Cell. Biol.
20:6587-6599 |
| 10. |
Durand, B.,
M. Kobr,
W. Reith, and B. Mach.
1994.
Functional complementation of major histocompatibility complex class II regulatory mutants by the purified X-box-binding protein RFX.
Mol. Cell. Biol.
14:6839-6847 |
| 11. |
Fontes, J. D.,
N. Jabrane-Ferrat,
C. R. Toth, and B. M. Peterlin.
1996.
Binding and cooperative interactions between two B-cell-specific transcriptional coactivators.
J. Exp. Med.
183:2517-2521 |
| 12. |
Fontes, J. D.,
B. Jiang, and B. M. Peterlin.
1997.
The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32.
Nucleic Acids Res.
25:2522-2528 |
| 13. |
Fontes, J. D.,
S. Kanazawa,
D. Jean, and B. M. Peterlin.
1999.
Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes.
Mol. Cell. Biol.
19:941-947 |
| 14. | Gourley, T., S. Roys, N. W. Lukacs, S. L. Kunkel, R. A. Flavell, and C. H. Chang. 1999. A novel role for the major histocompatibility complex class II transactivator CIITA in the repression of IL-4 production. Immunity 10:377-386[CrossRef][Medline]. |
| 15. | Griscelli, C., B. Lisowska-Grospierre, and B. Mach. 1989. Combined immunodeficiency with defective expression in MHC class II genes. Immunodeficiency Rev. 1:135[Medline]. |
| 16. |
Hake, S. B.,
K. Masternak,
C. Kammerbauer,
C. Janzen,
W. Reith, and V. Steimle.
2000.
CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation.
Mol. Cell. Biol.
20:7716-7725 |
| 17. |
Harton, J. A.,
D. E. Cressman,
K. C. Chin,
C. J. Der, and J. P. Ting.
1999.
GTP binding by class II transactivator: role in nuclear import.
Science
285:1402-1405 |
| 18. |
Heery, D. M.,
T. Zacharewski,
B. Pierrat,
H. Gronemeyer,
P. Chambon, and R. Losson.
1993.
Efficient transactivation by retinoic acid receptors in yeast requires retinoid X receptors.
Proc. Natl. Acad. Sci. USA
90:4281-4285 |
| 19. |
Inohara, N.,
T. Koseki,
L. del Peso,
Y. Hu,
C. Yee,
S. Chen,
R. Carrio,
J. Merino,
D. Liu,
J. Ni, and G. Nunez.
1999.
Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB.
J. Biol. Chem.
274:14560-14567 |
| 20. |
Inohara, N.,
T. Koseki,
J. Lin,
L. del Peso,
P. C. Lucas,
F. F. Chen,
Y. Ogura, and G. Nunez.
2000.
An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways.
J. Biol. Chem.
275:27823-27831 |
| 21. |
Jabrane-Ferrat, N., and B. M. Peterlin.
1994.
Ets-1 activates the DRA promoter in B cells.
Mol. Cell. Biol.
14:7314-7321 |
| 22. | Kajava, A. V. 1998. Structural diversity of leucine-rich repeat proteins. J. Mol. Biol. 277:519-527[CrossRef][Medline]. |
| 23. |
Kretsovali, A.,
T. Agalioti,
C. Spilianakis,
E. Tzortzakaki,
M. Merika, and J. Papamatheakis.
1998.
Involvement of CREB binding protein in expression of major histocompatibility complex class II genes via interaction with the class II transactivator.
Mol. Cell. Biol.
18:6777-6783 |
| 24. | Li, P., D. Nijhawan, I. Budihardjo, S. M. Srinivasula, M. Ahmad, E. S. Alnemri, and X. Wang. 1997. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479-489[CrossRef][Medline]. |
| 25. | Linhoff, M. W., K. L. Wright, and J. P. Ting. 1997. CCAAT-binding factor NF-Y and RFX are required for in vivo assembly of a nucleoprotein complex that spans 250 base pairs: the invariant chain promoter as a model. Mol. Cell. Biol. 17:4589-4596[Abstract]. |
| 26. |
Linhoff, M. W.,
J. A. Harton,
D. E. Cressman,
B. K. Martin, and J. P. Ting.
2001.
Two distinct domains within CIITA mediate self-association: involvement of the GTP-binding and leucine-rich repeat domains.
Mol. Cell. Biol.
21:3001-3011 |
| 27. | Louis-Plence, P., C. S. Moreno, and J. M. Boss. 1997. Formation of a regulatory factor X/X2 box-binding protein/nuclear factor-Y multiprotein complex on the conserved regulatory regions of HLA class II genes. J. Immunol. 159:3899-3909[Abstract]. |
| 28. | Mach, B., V. Steimle, E. Martinez-Soria, and W. Reith. 1996. Regulation of MHC class II genes: lessons from a disease. Annu. Rev. Immunol. 14:301-331[CrossRef][Medline]. |
| 29. |
Masternak, K.,
A. Muhlethaler-Mottet,
J. Villard,
M. Zufferey,
V. Steimle, and W. Reith.
2000.
CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex.
Genes Dev.
14:1156-1166 |
| 30. |
Mitts, M. R.,
D. B. Grant, and W. Heideman.
1990.
Adenylate cyclase in Saccharomyces cerevisiae is a peripheral membrane protein.
Mol. Cell. Biol.
10:3873-3883 |
| 31. | Moreno, C. S., G. W. Beresford, P. Louis-Plence, A. C. Morris, and J. M. Boss. 1999. CREB regulates MHC class II expression in a CIITA-dependent manner. Immunity 10:143-151[CrossRef][Medline]. |
| 32. | Nolte, R. T., G. B. Wisely, S. Westin, J. E. Cobb, M. H. Lambert, R. Kurokawa, M. G. Rosenfeld, T. M. Willson, C. K. Glass, and M. V. Milburn. 1998. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395:137-143[CrossRef][Medline]. |
| 33. |
Reith, W.,
C.-A. Siegrist,
B. Durand,
E. Barras, and B. Mach.
1994.
Function of major histocompatibility complex class II promoters requires cooperative binding between factors RFX and NF-Y.
Proc. Natl. Acad. Sci. USA
91:554-558 |
| 34. | Schneider, R., E. Schneider-Scherzer, M. Thurnher, B. Auer, and M. Schweiger. 1988. The primary structure of human ribonuclease/angiogenin inhibitor (RAI) discloses a novel highly diversified protein superfamily with a common repetitive module. EMBO J. 7:4151-4156[Medline]. |
| 35. |
Scholl, T.,
S. K. Mahanta, and J. L. Strominger.
1997.
Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5.
Proc. Natl. Acad. Sci. USA
94:6330-6334 |
| 36. |
Sisk, T. J.,
T. Gourley,
S. Roys, and C. H. Chang.
2000.
MHC class II transactivator inhibits IL-4 gene transcription by competing with NF-AT to bind the coactivator CREB binding protein (CBP)/p300.
J. Immunol.
165:2511-2517 |
| 37. |
Spilianakis, C.,
J. Papamatheakis, and A. Kretsovali.
2000.
Acetylation by PCAF enhances CIITA nuclear accumulation and transactivation of major hisocompatibility complex class II genes.
Mol. Cell. Biol.
20:8489-8498 |
| 38. | Steimle, V., L. A. Otten, M. Zufferey, and B. Mach. 1993. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 75:135-146[CrossRef][Medline]. |
| 39. |
Steimle, V.,
C.-A. Siegrist,
A. Mottet,
B. Lisowska-Grospierre, and B. Mach.
1994.
Regulation of MHC class II expression by interferon- -mediated by the transactivator gene CIITA.
Science
265:106-109 |
| 40. |
Villard, J.,
M. Peretti,
K. Masternak,
E. Barras,
G. Caretti,
R. Mantovani, and W. Reith.
2000.
A functionally essential domain of RFX5 mediates activation of major histocompatibility complex class II promoters by promoting cooperative binding between RFX and NF-Y.
Mol. Cell. Biol.
20:3364-3376 |
| 41. | Wright, K. L., B. J. Vilen, Y. Itoh-Lindstrom, T. L. Moore, G. Li, M. Criscitiello, P. Cogswell, J. B. Clarke, and J. P. Ting. 1994. CCAAT box binding protein NF-Y facilitates in vivo recruitment of upstream DNA binding transcription factors. EMBO J. 13:4042-4053[Medline]. |
| 42. | Zhou, H., H. S. Su, X. Zhang, J. Douhan III, and L. H. Glimcher. 1997. CIITA-dependent and-independent class II MHC expression revealed by a dominant negative mutant. J. Immunol. 158:4741-4749[Abstract] |
| 43. |
Zhu, X. S.,
M. W. Linhoff,
G. Li,
K. C. Chin,
S. N. Maity, and J. P. Ting.
2000.
Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter.
Mol. Cell. Biol.
20:6051-6061 |
| 44. | Zou, H., W. J. Henzel, X. Liu, A. Lutschg, and X. Wang. 1997. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90:405-413[CrossRef][Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. |
|---|